Dr. Weber on Unmet Needs in Melanoma


In Partnership With:

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

Jeffrey S. Weber, MD, PhD, ​deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses unmet needs in melanoma.

Patients ​with melanoma who have been surgically resected and rendered free of disease, but are still at high risk for relapse, represent a major unmet need in the space​, says Weber. The definition of high risk varies; however, it typically is defined by patients who have a​t least a 50% risk of relapse ​over 5 years. Moreover, given the modest toxicities observed with BRAF/MEK regimens, high risk could also be defined as anyone who has a 25% ​or greater risk of relapse over 5 year​s, Weber explains.

Additionally, patients with stage IIIC and IIID melanoma tend to have poor prognosis and represent a challenging population to treat, Weber says. Historically, seeking an optimal ​adjuvant therapy for these patients has been ​an area in need of additional research. Currently, treatment options include PD-1 inhibitors, such as nivolumab (Opdivo) or pembrolizumab (Keytruda), or BRAF/MEK inhibitors, such as dabrafenib (Tafinlar) and trametinib (Mekinist), Weber concludes.

Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Roisin E. O'Cearbhaill, MD
Stephen J. Freedland, MD
Tapan M. Kadia, MD,
Sara M. Tolaney, MD, MPH
Javier Cortés, MD, PhD,
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD